Published in Biotech Law Weekly, November 11th, 2005
AMD is the leading cause of legal blindness effecting more than 50 million people worldwide. The trial showed that in 2 weeks 26% of the eyes treated had improved vision by 10 letters or more, the equivalent of two lines on the eye chart. There were zero serious adverse events.
TheraMac produces minute amounts of electrical biocurrent that is delivered to the retina through a probe touching the skin around the eye. The biocurrent facilitates increases in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.